Abstract:AIM:To examine the effect of celecoxib on tumor growth and angiogenesis in an orthotopic implantation tumor model of colon cancer.METHODS:Human colorectal adenocarcinoma HT-29 cells were implanted subcutaneously in nude mice. Four groups of animals received different doses of celecoxib after tumor implantation. After 42 days, all animals were evaluated for changes in body weight, the volume and weight of colorectal tumors, and tumor growth inhibition. The content of prostaglandin E(2) (PGE(2)) in the tumor tissue homogenate was estimated by radioimmunoassay (RIA). Cyclooxygenase-2 (COX-2) and CD34 expression in tumor tissue was assessed by immunohistochemistry, and the microvessel density (MVD) of tumor tissue was determined. Apoptosis of the tumor cells was detected by the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL). The expression of vascular endothelial growth factor (VEGF) mRNA and matrix metalloproteinase-2 (MMP-2) mRNA extracted from the tumor tissue was analyzed by reverse transcriptase polymerase chain reaction (RT-PCR).RESULTS:There was no statistically significant change in the animals' body weight between the treatment groups. However, with increasing doses of celecoxib, the volume and weight of the tumor decreased. The rates of tumor growth inhibition for the L (low), M (medium) and H (high) groups were 25.30%, 38.80%, and 76.92%, respectively, which were significant compared to the C (control) group. There were significant differences in COX-2 expression in the tumor tissue between all groups, except between the L and M groups. Celecoxib exposure also reduced PGE2 levels in the tumor tissue homogenates. The level of PGE(2) correlated to the weight of tumor (r=0.8814, P < 0.05) and to COX-2 expression (r=0.8249, Puse < 0.05). Compared to the control group, the tumor cells from celecoxib-treated mice had a significantly higher apoptotic index. Celecoxib also decreased CD34(+) expression in tumors from treated mice. There were significant differences in the MVD between all groups except between groups H and M. Celecoxib significantly reduced the expression of VEGF and MMP-2 mRNA in the group H but not in L and M groups. The MVD in tumor tissue was closely related to the PGE2 levels, as well as the expression of VEGF and MMP-2 mRNA (r = 0.9006, r = 0.8573 and r = 0.6427, respectively; P < 0.05).CONCLUSIONS:By inhibiting COX-2, PGE(2) synthesis, and VEGF and MMP-2 mRNA expression in tumor tissue, celecoxib enhances tumor cell apoptosis, thereby inhibiting the growth and angiogenesis of orthotopically implanted tumors in a mouse model of human colorectal cancer.

c-Met inhibition is required for the celecoxib-attenuated stemness property of human colorectal cancer cells

Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity

Celecoxib Downregulates Cd133 Expression Through Inhibition of the Wnt Signaling Pathway in Colon Cancer Cells

Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN.

Simultaneous inhibition of EGFR/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cells

Synergistic Antitumor Effects of Cmet Inhibitor in Combination with Anti-Vegf in Colorectal Cancer Patient-Derived Xenograft Models

Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum

Celecoxib Enhances Anticancer Effect of Cisplatin and Induces Anoikis in Osteosarcoma Via PI3K/Akt Pathway.

Selective Cox-2 Inhibitor Celecoxib Induces Epithelial-Mesenchymal Transition in Human Lung Cancer Cells Via Activating MEK-ERK Signaling

Celecoxib Induces Cell Apoptosis Coupled with Up-Regulation of the Expression of Vegf by A Mechanism Involving Er Stress in Human Colorectal Cancer Cells

Celecoxib Inhibits Tumor Growth and Angiogenesis in an Orthotopic Implantation Tumor Model of Human Colon Cancer.

PC‐407, a Celecoxib Derivative, Inhibited the Growth of Colorectal Tumor in Vitro and in Vivo

Multiomics Study of a Novel Naturally Derived Small Molecule, NSC772864, as a Potential Inhibitor of Proto-Oncogenes Regulating Cell Cycle Progression in Colorectal Cancer

Celecoxib induces apoptosis but up-regulates VEGF via endoplasmic reticulum stress in human colorectal cancer in vitro and in vivo

Dual Inhibition of Met and Src Kinase Activity As A Combined Targeting Strategy for Colon Cancer

Celecoxib Enhances the Radiosensitivity of HCT116 Cells in a COX-2 Independent Manner by Up-Regulating BCCIP.

Increase of Cyclooxygenase-2 Inhibition with Celecoxib Combined with 5-FU Enhances Tumor Cell Apoptosis and Antitumor Efficacy in a Subcutaneous Implantation Tumor Model of Human Colon Cancer

ADT-OH Synergistically Enhanced the Antitumor Activity of Celecoxib in Human Colorectal Cancer Cells.

The Molecular Mechanisms of Celecoxib in Tumor Development

Modulating Effect of Celecoxib to Suppress Proliferation and the Molecular Mechanism in Caco-2 of Colon Carcinoma Cell Line

Mechanism of inhibition of growth and metastasis of colon cancer by celecoxib analog OSU-03013 via wnt signaling pathway